Side-by-side comparison of AI visibility scores, market position, and capabilities
Tortus AI provides an AI agent that sits alongside clinicians during patient visits, automatically generating clinical notes and handling documentation tasks in real time.
Tortus AI is a healthcare AI company founded in 2022 in London that develops an AI agent designed to reduce the documentation burden on physicians and clinical staff. The platform operates as a persistent AI presence during clinical encounters, listening to patient-clinician conversations and automatically generating structured clinical notes, coding suggestions, referral letters, and other administrative documentation. Unlike simple transcription tools, Tortus AI interprets clinical context to generate documentation that conforms to specialty-specific formats and coding requirements. The company serves NHS trusts and private healthcare organizations in the United Kingdom and is expanding internationally. Physician burnout driven by excessive documentation requirements is a critical healthcare workforce crisis, with doctors spending roughly half their working time on administrative tasks rather than patient care. Tortus AI addresses this directly by taking over documentation workflows and allowing clinicians to focus on clinical reasoning and patient relationships. The company raised $12M and has deployed across multiple clinical specialties including primary care, emergency medicine, and outpatient specialties with strong clinician satisfaction rates.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.